Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial - Wikidata - wikimedia - TriplyDB

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial

http://www.wikidata.org/entity/Q34562259

about

Recent update in HIV vaccine development Sieve analysis in HIV-1 vaccine efficacy trials HIV-1 neutralizing antibodies: understanding nature's pathways Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection A global approach to HIV-1 vaccine development Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIV HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials.Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel.HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.HIV-1 vaccines: challenges and new perspectives Novel directions in HIV-1 vaccines revealed from clinical trials Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.Which Antibody Functions are Important for an HIV Vaccine?Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1 Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.Cryptic determinant of α4β7 binding in the V2 loop of HIV-1 gp120.Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2.Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses Receptor binding domain based HIV vaccines.Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus.Human immunodeficiency virus vaccines A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.

P2860

Q26766628-F9977C16-09D9-4896-B6A0-2B3C4D8E88E0 Q26851376-DCF364B1-9A7C-49E9-ABDA-EDB4E16A889C Q27000480-22E05D2C-BE2D-45D7-8190-8D31AE27637C Q27022652-E9A53F05-AC4E-4A56-A65E-186AA97131EF Q27024614-66AF33D6-863D-42BC-8A12-DB287B320BEA Q27681527-CFB889EA-0DB7-42DF-8A27-D8E1EDAA865B Q27687375-50E61FFC-0A79-41AE-88CF-37DB46359104 Q28728517-0A93062E-0205-48F0-823E-F10251B8E2AE Q28830298-E92A26CA-8E0C-4C1C-9A13-13D14632E7D5 Q30152923-274393E7-328B-4EE3-9E11-0E71D9830742 Q30355260-68B08675-42FE-4370-B0AE-F1412F300626 Q30375785-545D9101-5E09-46BF-B6E5-D6CEA5DD3998 Q33577972-CAD79684-CD55-4475-983B-3CD26854E671 Q33645528-4A877698-25C2-4EAB-806C-68660B9668F9 Q33712296-99FB801F-9C79-4F96-B5B5-E55CB47501D3 Q33742529-B66DDA99-8757-453C-A424-A73B06A0F90A Q33772637-26373927-5D43-4B53-8452-E019AA52B15A Q33813145-38299EA3-9C2F-4894-A0C5-B45350DBB8D3 Q33865785-DAE03A87-922F-4C78-836A-0C199BF11FAC Q33874253-A8619184-658E-494A-85F5-7AB584C5C915 Q33947008-74CA2B10-D2D7-4925-8B4D-E830A3E4065F Q33977866-998A43AA-750B-45F2-AABF-2279D5F47272 Q34057711-F001CAD7-26A0-45C7-B1F6-835ADC1C6B03 Q34057942-A2B35673-88A3-4477-9F3A-FAF5AF6AB927 Q34117524-B448F7C7-13A0-4FE4-97ED-449AF006C31B Q34270309-ACE30110-EF89-43C4-84BF-39B85BD53058 Q34374835-1AD9DEFD-04D0-4C59-B0B2-B9EF41D71BB5 Q34402934-C2B018BF-E836-4A28-8D42-DCC1B459166C Q34480617-B46F5A92-4E55-4012-BC75-9B8642E8F0C3 Q34499013-676952EF-6F57-4BFF-88BE-6FB19B5F2785 Q34540352-F7ED05F7-473F-492D-B2D0-8F4E60250FD3 Q34594513-52DC85AE-38D2-4ACF-AE9B-DE4B1D0C38CA Q34616275-1A3EC95C-D3A9-470F-B18B-5C3CF6C19CF8 Q34907398-1C1AC7CA-D835-4E1C-BFB7-9DC79571EE88 Q34948847-65C7659E-BECD-4196-9A5A-4FF8DC9230BE Q35033862-F1EA643E-AD0A-4C64-963E-CF135C4C72C2 Q35055183-A8228A2A-0AD8-4A79-9A09-0BCE34311BB4 Q35069151-A7275932-E95C-4738-AFB1-F77209F715CF Q35674731-26D4A7D0-3214-4BEC-ABF2-E5B80AB6A171 Q35706462-C6A733C6-19F4-41F9-A9F9-4BADAE4B348E

P2860

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial

http://www.wikidata.org/entity/Q34562259

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Analysis of V2 antibody respon ...... X HIV-1 vaccine efficacy trial

@ast

Analysis of V2 antibody respon ...... X HIV-1 vaccine efficacy trial

@en

Analysis of V2 antibody respon ...... X HIV-1 vaccine efficacy trial

@nl

type

label

Analysis of V2 antibody respon ...... X HIV-1 vaccine efficacy trial

@ast

Analysis of V2 antibody respon ...... X HIV-1 vaccine efficacy trial

@en

Analysis of V2 antibody respon ...... X HIV-1 vaccine efficacy trial

@nl

prefLabel

Analysis of V2 antibody respon ...... X HIV-1 vaccine efficacy trial

@ast

Analysis of V2 antibody respon ...... X HIV-1 vaccine efficacy trial

@en

Analysis of V2 antibody respon ...... X HIV-1 vaccine efficacy trial

@nl

P1433

Q34562259-44395729-563A-4B9E-A5E2-15CEEB1E6934

P1476

Q34562259-7C8275A3-12D8-4BF8-9F93-670933E1705A

P2093

Q34562259-1353BF9F-4FD7-4DBF-A93D-ECA5AAA6922C

Q34562259-16527B98-94AA-4055-BE52-0850EFBBAEB4

Q34562259-358C55F4-766B-4E55-8CC3-87ABF4CA4F5F

Q34562259-36E048F9-AB99-4739-86DA-224BDCD7CFF9

Q34562259-37269390-CFF3-424D-A2FC-1886C334D0C1

Q34562259-3B6F22A7-D796-4617-A9F1-43E74DEEBCB0

Q34562259-442D41A9-3760-408B-BC95-EA4690898BEE

Q34562259-55B539C1-7613-4DFF-B06D-EF7815D6B227

Q34562259-602DD126-AF88-4CAB-AAC5-E8FD271180D1

Q34562259-6F21F4E9-EC26-45AE-8FDB-57E6312871E8

P2860

Q34562259-00A9CB21-DCFE-4CAE-97C9-AA2A9932C033

Q34562259-0A0624AD-26E5-4873-B3A9-D465E8230D69

Q34562259-16104B20-9035-4678-A7E9-FC99C385E235

Q34562259-17BED78E-94D5-4573-9D69-0949F559733A

Q34562259-2AA35A4C-04EF-4C9A-9AB4-0BF903BCC379

Q34562259-3313A16E-C3AE-4000-BD70-3E1AC62B7887

Q34562259-35C4FF91-E286-47CD-B04C-79B8A2E0A106

Q34562259-371439EB-DAC0-40BB-8CED-DD48AF8676F1

Q34562259-3F0E777A-22C9-4AE3-9ECB-0F77E6CE087A

Q34562259-40E989EB-B989-4011-8C3A-4B6A7215669A

P304

Q34562259-E10BB2D1-F108-40B4-AE44-DB8FD352DF2A

P31

Q34562259-8E85B4AD-80D9-4604-B4E2-CB3AC3DE3A4C

P356

Q34562259-E539C8FC-6B08-4481-80D8-EF4527595A27

P407

Q34562259-496D765E-AB62-49D2-91EA-100D5A9F2303

P433

Q34562259-EAB8422A-E984-45B8-8205-C10F4A43064D

P478

Q34562259-ACFAE52D-DBE6-4E2D-9B2D-03A08E25BCAF

P50

Q34562259-09A0D6B7-C717-42EA-9E46-AB5FE4EE2640

Q34562259-16D7BD35-525C-4420-B6D4-91F2ECFD8751

Q34562259-58146372-5520-4E99-A222-0E84D0E1C1F4

Q34562259-5F1A3246-2E85-42C0-898D-CFF1847CE6E0

Q34562259-7BEECF01-6769-4B54-8A35-C624ACEC3190

Q34562259-9899AD93-1F96-484E-BE63-19EE9A4151A5

Q34562259-A57172E7-F3BB-4997-B93A-E9E41A434A5D

Q34562259-E610CB68-3117-46E4-9705-CA00925CEB5C

Q34562259-F6BA5D19-A582-4524-8B0B-6BE4781408BB

P577

Q34562259-7D298BF2-9871-4658-8B48-29CB9062234B

P5875

Q34562259-02AAA8F1-CB8B-4E28-AEC8-D2BF4EC6D484

P698

Q34562259-838F10DB-79AA-4212-84B8-CE6F5B6CD6B3

P921

Q34562259-BB7CA74E-9E3F-4B24-813D-59E656C639D3

P932

Q34562259-454FB0AE-41A8-41AF-B748-99EFC38D7723

P356

JOURNAL.PONE.0053629

P1433

P1476

Analysis of V2 antibody respon ...... X HIV-1 vaccine efficacy trial

@en

P2093

Abraham Pinter

http://www.w3.org/2001/XMLSchema#string

Allan C deCamp

http://www.w3.org/2001/XMLSchema#string

Charla Andrews

http://www.w3.org/2001/XMLSchema#string

Constance Williams

http://www.w3.org/2001/XMLSchema#string

Daryl E Morris

http://www.w3.org/2001/XMLSchema#string

Erik Billings

http://www.w3.org/2001/XMLSchema#string

Mangala Rao

http://www.w3.org/2001/XMLSchema#string

Mark de Souza

http://www.w3.org/2001/XMLSchema#string

Nicos Karasavvas

http://www.w3.org/2001/XMLSchema#string

Peter B Gilbert

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1

Structural Analysis of Human and Macaque mAbs 2909 and 2.5B: Implications for the Configuration of the Quaternary Neutralizing Epitope of HIV-1 gp120

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding

P304

e53629

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0053629

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

David C Montefiori

Georgia Tomaras

Supachai Rerks-Ngarm

P577

2013-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235372080

http://www.w3.org/2001/XMLSchema#string

P698

23349725

http://www.w3.org/2001/XMLSchema#string

P921

P932

3547933

http://www.w3.org/2001/XMLSchema#string